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Photodynamic therapy (PDT) for treatment of lung cancer has
been investigated extensively with the use of Photofrin as a photo-
sensitizer (McCaughan et al, 1988; Hayata et al, 1996; Lam, 1994)
for palliation, as well as with curative intent for treatment of early-
stage lung cancer. Cortese et al (1997) showed that PDT with
haematoporphyrin derivative (HpD) can be an alternative to
surgery. Currently, the use of meta-tetrahydroxyphenyl chlorin
(mTHPC) as a photosensitizing agent is being evaluated experi-
mentally and clinically for the treatment of cancer of the lungs,
oesophagus and larynx (Abramson et al, 1994; Lofgren et al, 1994;
Grosjean et al, 1996).
The common method of light delivery in this application of
PDT is the use of a linear (or cylindrical) diffuser, which is suited
to illuminate hollow, cylindrical organs such as the trachea or the
bronchi. The light dosimetry of this treatment consists of a
measurement of the total output of the linear diffuser only, and the
applied ‘light dose’ is defined as the total amount of light energy
emitted per unit of length of the diffuser (J cm–1). Little is known
about other important factors that determine the light fluence rate
(and fluence) distribution in the tissue, which is the appropriate
‘light dose’ to evaluate PDT effects.
In previous work we showed that the in situ fluence rate
resulting from illumination of the bronchi with identical diffusers
and output can vary considerably between individuals (Murrer
et al, 1997a). This is related to the inter-individual variations in
optical properties of the bronchial mucosa. Similar variations in
fluence rate caused by variations in optical properties (with red
light of 630 nm) are found in the bladder (D’Hallewin et al, 1992)
and in the skin (Hudson et al, 1994). In addition, the positioning of
the diffuser in the lumen (Marijnissen et al, 1993; Murrer et al,
1995) and the output characteristics of the linear diffuser used
(Murrer et al, 1996) have great influence on the fluence rate distri-
bution in the tissue.
Because so many, sometimes unknown, parameters can influ-
ence the fluence rate in the mucosa, it is necessary to perform an in
situ measurement of the fluence rate to quantify the applied
fluence. An applicator which makes it possible to perform such a
measurement together with a controlled way of light delivery has
been developed in our group (Murrer et al, 1997a). With the help
of this applicator, the present study seeks to find a relationship
between the applied fluence (true ‘light dose’) and the short-term
(1–2 days) damage found in the normal (healthy) tracheal mucosa
resulting from PDT with Photofrin or mTHPC. Consequently, the
long-term damage resulting from an applied fluence that results in
potentially recoverable short-term damage is investigated to deter-
mine the tolerance of normal tissue to PDT.
METHODS
General protocol
The study was performed in two parts. In the first (acute) part the
normal tissue damage of the bronchial mucosa caused by PDT in
the trachea of healthy pigs was assessed visually as well as histo-
logically 24 and 48 h after illumination. Either mTHPC or
Photofrin was used. The photosensitizer dose was kept the same in
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all experiments and the total light fluence was varied (with
constant fluence rate) in three areas in the trachea of each pig. This
part served as a fluence-finding experiment for the second part. In
the second part, one single total light fluence was applied and the
bronchial mucosa damage was followed visually during the 2
weeks follow-up period and histologically after termination of the
experiment. The total light fluence applied in the second part is the
fluence that showed potentially recoverable damage in the first
part for each drug applied. The experimental protocol (no.
604-96-02) adhered to rules laid down in the Dutch Animal
Experimentation Act and was approved by the Committee on
Animal Research of the Erasmus University Rotterdam.
Animals and anaesthesia
The animals used in this study were female pigs of a cross-breed of
Danish Landrace and Yorkshire pigs (~ 30 kg). The animals were
kept on a standard diet. The day before treatment, as well as the
day before follow-up bronchoscopy, they were kept fasted. For all
procedures the animals were sedated with ketamine (intramuscu-
larly, 10 mg kg–1) and intubated. They were ventilated artificially
with a mixture of nitrous oxide:oxygen (1:2 v:v) and 1.5% isoflu-
rane. During ventilation, anaesthesia was maintained with panco-
rium (intravenously (i.v.) 4 mg) and fentanyl (i.v., 0.1 mg). After
the experimental procedures the animals were hand-ventilated
until independent breathing was restored. During the treatment the
artificial ventilation duration never exceeded 45 min, during drug
delivery and follow-up bronchoscopies the duration was less then
15 min. During drug delivery the animals were ventilated with a
mask only and received no additional i.v. anaesthesia. The animals
were sacrificed with a bolus injection of pentobarbital (i.v.).
Drug delivery
In both the acute and follow-up part six animals were used. In each
part two animals received PhotofrinTM and four animals received
mTHPCTM. The Photofrin was kindly provided by Quadra Logic
Technologies (Vancouver, Canada) and the mTHPC was kindly
provided by Scotia Quantanova (Guildford, Great Britain).
The Photofrin was dissolved in a 5% dextrose solution and
administered i.v. by a slow-push injection 48 h before treatment
according to the Lederle/QLT protocol (P 503/504) for endo-
bronchial PDT. The applied dose was 2 mg per kg bodyweight.
The mTHPC was dissolved in a mixture of ethanol, polyethylene
glycol and water that was supplied with the drug, and injected
i.v. by a slow-push injection 96 h before treatment. This drug
delivery-illumination interval is also used by other groups for
mTHPC–PDT (e.g. Grosjean et al, 1996). The applied dose was
0.15 mg per kg bodyweight. The animals were housed separately
in subdued light conditions during the entire study.
Light delivery and dosimetry
The light was delivered using an applicator that was specifically
developed for endobronchial PDT. The applicator incorporates a
linear diffuser for light delivery, a fixation system that ensures the
Table 1 Summary of the treatment parameters and light dosimetry
No. Site Sensitizer Interval Sacrificed Fluence rate Output Total Diameter b
injection-treatment on day (mW cm–2) applicator fluence trachea (± 20%)
(days) (± 15%) (mW), (J cm–2), (cm),
(± 5%) (± 15%) (± 5%)
Acute
dist mTHPC 4 1 400 796 50 1.0 2.6
1 mid mTHPC 4 1 400 796 25 1.0 2.6
prox mTHPC 4 1 400 507 12.4 1.3 5.4
dist mTHPC 4 1 400 859 50 0.9 2.0
2 mid mTHPC 4 1 400 979 25 1.0 2.1
prox mTHPC 4 1 400 919 12.7 1.0 2.1
dist Photofrin 2 1 270 600 274 1.0 2.1
3 mid Photofrin 2 1 257 600 133 0.8 1.6
prox Photofrin 2 1 330 600 79 0.9 2.4
dist mTHPC 4 2 400 1350 51 1.2 1.8
4 mid mTHPC 4 2 400 1480 25 1.0 1.3
prox mTHPC 4 2 400 1220 12.6 1.2 2.0
dist mTHPC 4 2 400 1474 50 1.2 1.6
5 mid mTHPC 4 2 400 1288 25 1.2 1.8
prox mTHPC 4 2 400 1165 12.7 1.2 2.0
dist Photofrin 2 2 188 600 190 1.2 2.0
6 mid Photofrin 2 2 178 600 90 1.0 1.4
prox Photofrin 2 2 195 600 50 0.9 1.4
Follow-up
1 mTHPC 4 14 400 584 50 1.2 4.1
2 mTHPC 4 10a 400 605 50 1.1 3.7
3 Photofrin 2 –b –– – – –
4 mTHPC 4 14 400 468 50 1.1 4.7
5 mTHPC 4 14 400 620 50 1.2 4.1
6 Photofrin 2 14 375 450 65 1.0 3.9
mTHPC dose was 0.15 mg kg–1 bodyweight, Photofrin dose 2 mg kg–1 bodyweight. aSacrificed earlier because of non-PDT skin damage. bExcluded from the
experiment because of uncertainty of the light dose applied. b is the measured fluence rate divided by the incident fluence rate. For further explanation see text.746 LHP Murrer et al
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central positioning of the diffuser in the trachea and an isotropic
probe for in situ measurement of the fluence rate on the trachea
wall (Murrer et al, 1997a). A schematic of the endobronchial
applicator is presented in Figure 1.
The design has been improved with a 1.5 cm diffuser with
isotropic instead of forward scattering properties (Murrer et al,
1997b) manufactured by Rare Earth Medical (West Yarmouth,
MA, USA). The isotropy of the diffuser causes the maximum of
the fluence rate to be located on the trachea wall opposite the
middle of the diffuser. The isotropic probe measures the fluence
rate at this maximum.
With the aid of a Monte Carlo model for the geometry of a linear
diffuser in a trachea (Murrer et al, 1995) we estimated an overlap of
less than 5% of the maximum fluence rate between separate fields
when a diffuser of 1.5 cm was used with an inter-lesion spacing of
5 cm. This is possible in the pig’s trachea which is generally longer
than the 15 cm (3 ´ 5 cm) needed for the experiment.
The diameter of the isotropic probe fibre core has been
increased by a factor of two compared to our first design, which
causes a higher light output of the isotropic probe, enabling a
more sensitive measurement. The isotropic probe (bulb diameter
0.8 mm) mounted on a 200 mm quartz core fibre was produced
by Rare Earth Medical (West Yarmouth, MA, USA).
The light source used was a KTP/Nd:YAG laser with a dye unit
(KTP/YAG 832 and Dye module series 600; Laserscope, San Jose,
CA, USA) that was tuned to a wavelength of 652 or 630 nm for
mTHPC or Photofrin respectively. The output of the linear diffuser
was measured with an integrating sphere. The applicator was
inserted in the sphere, unfolded and the laser was switched on. The
voltage reading of a built-in photodiode was converted to the total
output in mW with appropriate calibration factors for the two
wavelengths used. The same integrating sphere was used to cali-
brate the isotropic probe in air (van Staveren et al, 1995). Built-in
laser diodes provided a stable diffuse light field, which was cali-
brated with the same photodiode that was used for the output
measurement. The output voltage of the photodiode was multi-
plied by an appropriate calibration factor to calculate the diffuse
light field in the sphere for both wavelengths used.
When in contact with tissue, the reading of the isotropic probe
calibrated in air has to be corrected because of the difference of
refractive index (n) between air (n = 1) and tissue (n = 1.37). When
the probe is pressed against the mucosa, the reading of the probe
calibrated in air has to be multiplied by a factor 1.07 (± 2%)
(Murrer et al, 1995, Marijnissen and Star, 1996). It is important
that the isotropic probe is kept free of mucus and blood to ensure
correct calibration. This can be checked through the bronchoscope
and, if necessary, the probe must be rinsed through the broncho-
scope or the applicator must be retracted, cleaned and inserted
again (Murrer et al, 1997a). The light output of the isotropic probe
was coupled to a photodiode inside a home-built dosimetry device,
which displays the fluence rate as well as the integrated fluence
rate in time (total fluence). The dosimeter is calibrated by inserting
and unfolding the applicator in the sphere with the laser diodes
switched on.
Applied fluences
The fluence rates and the total fluences that were applied for the
different sensitizers in the acute experiment were derived from
either an existing protocol (Photofrin) or from protocols for, e.g.
skin or ENT application (mTHPC) in humans.
The mTHPC-treatment fluence and fluence rate was derived
from the incident fluences and fluence rates in protocols for, e.g.
skin, where an incident fluence rate of 100 mW cm–2 is used to a
total incident fluence of 10 J cm–2. In a pilot experiment on rats, we
observed that the incident fluence rate on a shaved spot of skin
(2 cm diameter) increased to 250% by backscattering. This factor
serves as an approximation of the translation between the measure-
ment of the incident fluence (irradiance) with a flat detector and
the actual fluence rate measured with an isotropic probe touching
the skin. Therefore we decided to take 2.5 times 10 J cm–2 (flat
detector) = 25 J cm–2 (isotropic probe) as the central fluence and
half and twice that fluence (12.5 and 50 J cm–2) for the other two
illumination fields. The highest total fluence was used on the field
most distal to the animal’s head, and the fluence decreased with
more proximal location, thereby ensuring minimal relative overlap
between illumination fields.
The increase of fluence rate (or fluence) above the incident irra-
diance (or incident fluence) at the surface of the mucosa appears to
violate conservation of energy, but this is not the case. The fluence
is a measure for the amount of energy available for absorption at a
given point in the tissue. The actual amount of energy deposited in
a volume element of the tissue is given by the fluence times the
local absorption coefficient. Conservation of energy requires that
the summation of the product of fluence and absorption coefficient
over the entire volume equals the amount of energy in the incident
beam minus losses in the form of reflection from and transmission
through the medium.
Figure 2 shows the fluence rate in the tissue as a function of the
distance from the surface. The (infinitely wide) surface is illumi-
nated with a wide, collimated beam of light. The absorption and
scattering properties used for the calculations are typical for
bronchial mucosa at a wavelength of 630 nm (Murrer et al, 1995).
In one case (solid line), the scattering by the tissue has been
‘switched off’, and the fluence rate decreases exponentially from
the level of the incident irradiance (1 in the graph) at the tissue
surface.
The second graph (dashed line) clearly shows the influence of
scattering. The light scattering by the tissue causes the photons to
deviate from their straight paths in the tissue, causing more light to
be accumulated at relatively lower depths. As a result the fluence
rate near the surface is increased 5–6 times compared to the inci-
dent irradiance (this factor depends on the exact optical properties
of the tissue). Deeper in the tissue the fluence rate for the case with
scattering drops below the fluence rate for the case without scat-
tering. In short: increased scattering leads to higher fluence rates
near the surface and shallower penetration of the light. The area
under the curve for both sets of optical properties multipied by the
absorption coefficients is a measure for the energy deposited in the
tissue.
For superficial tumours (< 1 mm thickness) the fluence rate is
nearly constant over the lesion volume, unless the lesion has an
extremely (» 1 cm–1) high absorption coefficient in the case of
highly pigmented (tumour) tissue. The biological effect of PDT is
then determined by the product of fluence and absorption coeffi-
cient of the photosensitizer (neglecting fluence rate effects).
Surface light dosimetry is adequate in this case. Consider the
optical properties of Figure 2. If the absorption coefficient of the
photosensitizer is the same in both cases, the same biological
effect requires a 5.7-fold smaller incident fluence in the case with
light scattering, compared to zero light scattering, to achieve the
same total fluence. For non-superficial tumours, the fluence at thePhotofrin versus mTHPC 747
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deepest boundary with normal tissue should be considered. If the
lesion thickness is about 6.6 mm (optical properties of Figure 2),
the fluence rate at this depth is the same, if the incident fluence is
the same for both sets of optical properties. If the absorption coef-
ficient of the photosensitizer is the same in both cases, the light
fluence to be delivered at 6.6 mm depth is the same, so that the
incident surface fluence to be applied in the case with light
scattering should be the same as for the non-scattering case. If the
tumour thickness is larger than 6.6 mm, all optical properties
remaining the same, the incident fluence in the case with light
scattering should be larger than without scattering, to achieve the
same PDT effect at the deepest tumour–normal tissue boundary.
For non-superficial lesions then, one needs a technique to measure
the tumour thickness and a measurement of the light fluence at the
appropriate depth.
To rule out fluence rate effects, the fluence rate was kept constant
and the illumination time was varied to achieve different total
fluences. The fluence rate was set at 400 mW cm–2 as measured on
the isotropic probe because this is the fluence rate we expected to
find in the Photofrin treatment, based on ex vivo measurements
(Murrer et al, 1995). Using the 2.5 times build-up factor described
above, this fluence rate is equivalent to an incident collimated irra-
diance of about 160 mW cm–2, comparable to incident fluence rates
commonly used in mTHPC and Photofrin protocols. Treatment
times were 62.5, 125 and 250 s for the three fields.
The protocol for Photofrin (QLT/Lederle P 503/504) prescribes
a light output of 400 mW per cm diffuser length used for a dura-
tion of 500 s, yielding a total of 200 J per cm diffuser length. In the
acute experiment we applied this protocol in one of the three fields
illuminated. The other two fields were illuminated with half and
twice this energy viz. 100 and 400 J per cm diffuser length with
the same output in mW of the diffuser. The variation in energy
applied was achieved by varying the time of exposure, leading to
treatment times of 250, 500 and 1000 s.
Again the field with the highest total fluence was chosen most
distally to the head of the animal and the resulting fluence rate and
total fluence on the probe were recorded. The measured total
fluence was used to determine a total fluence for the follow-up
part of the experiment. In the follow-up part, the fluence rate on
the probe was set at » 400 mW cm–2 (the same as the mTHPC
experiment) and then the illumination was continued until the
desired total fluence was reached.
Build-up factor
Because of the scattering properties of the illuminated tissue, the
fluence rate resulting from the illumination with the diffuser will
be higher than the incident fluence rate on the mucosa. For
diffusers with good isotropic properties (as used in our applicator)
the maximum incident fluence rate for central placement in the
lumen j0 (mW cm–2) can be calculated from (Murrer et al, 1995):
j0 = P/pLD arctan (L/D) (1)
with P the total output power of the diffuser (mW), L the length of
the diffuser (cm) and D the diameter of the trachea (cm).
The build-up factor b is defined as the ratio of the measured
fluence rate jtrue and the incident fluence rate,
b = jtrue/j0 (2)
and depends on the optical properties of the mucosa.
Treatment
The respiration tube (diameter 9 mm) was fixed just below the
larynx to leave a maximum length of trachea exposed to be used
Table 2 Visual damage score for acute and follow-up experiment
Acute
Sacrificed after 1 day 2 days
Animal 1 2 3 4 5 6
Sensitizer mTHPC mTHPC Photofrin mTHPC mTHPC Photofrin
Site D M P D M P D M P D M P D M P D M P
Redness 0 0 0 0 0 0 2 2 1 0 0 0 0 0 0 2 2 1
Whiteness 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 0 0 0
Oedema 0 0 0 0 0 0 2 2 1 0 0 0 0 0 0 2 2 1
Mucus 1 1 1 0 0 0 1 1 1 0 0 0 0 0 0 1 1 1
Follow-up
Animal 1 2a 3b
Sensitiser mTHPC mTHPC Photofrin
Day 1 3 7 10 14 1 3 7 10 14 1 3 7 10 14
Redness 0 0 0 0 0 0 1 0 0 – – – – – –
Whiteness 0 0 0 1 0 0 0 0 0 – – – – – –
Oedema 0 0 0 0 0 0 0 0 0 – – – – – –
Mucus 0 0 1 1 0 0 0 1 0 – – – – – –
Animal 4 5 6
Sensitizer mTHPC mTHPC Photofrin
Day 1 3 7 10 14 1 3 7 10 14 1 3 7 10 14
Redness 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0
Whiteness 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Oedema 0 1 0 0 0 0 1 0 1 0 0 0 1 0 0
Mucus 0 1 0 0 0 0 1 0 0 0 0 1 0 0 1
0 = none/normal, 1 = some/slight increase, 2 = much, – = not available. D = distal, M = middle, P = proximal. aSacrificed on day 10 because of (non-PDT) skin
damage. bExcluded from experiment because of unreliable dosimetry.748 LHP Murrer et al
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for illumination. A fibre bronchoscope with a large working
channel (diameter 2.8 mm, Fujinon Medical Holland) was intro-
duced through the tube, and the applicator was fed through the
working channel. During this procedure the artificial ventilation
was maintained through the open space between the bronchoscope
and the tube. After unfolding the applicator the positioning of the
detector was checked through the bronchoscope to ensure good
contact with the mucosa and to ensure that there was no blood or
mucus on the probe. The relative position of the applicator in the
trachea was measured by the markings on the bronchoscope rela-
tive to the teeth of the animal. The larynx served as a reference for
the zero position.
The applicator was fixed in the trachea such that the most prox-
imal position was not too close to the tube to avoid reflections off
the tube. In the case of the acute Photofrin treatment, the output of
the diffuser was preset to a fixed output of 600 mW defined by the
Photofrin protocol (1.5 cm diffuser ´ 400 mW cm–1) and the time
of exposure was measured. The resulting fluence rate and total
fluence were recorded. In the other cases the laser was switched on
and the output was adjusted such that the probe reading was
400 mW cm–2, and kept at that level by adjusting the output if
necessary. The treatment was halted when the desired total fluence
was achieved. After the treatment the output of the applicator was
measured, and the calibration of the probe was checked.
In the acute experiment half of the animals (one Photofrin, two
mTHPC) were sacrificed at 24 and the other half at 48 h. In the
follow-up experiment the animals were sacrificed after 14 days.
On days 1, 3, 7, 10 and 14 the animals’ tracheas were examined by
bronchoscopy. In the case of excessive damage, the experiment
was to be terminated earlier.
Precautions
Several precautions were taken to avoid damage related to non-
treatment light. During transport to and from the operating theatre
the animals were shielded from light with dark cloth. In the oper-
ating theatre only necessary lights were left on, and those were not
directed at the animals. The animals were also covered with dark
cloth in theatre. The bronchoscope’s light source was operated on
the lowest setting allowing good visual control of the situation.
During treatment the light source was switched off entirely. The
duration of bronchoscopy with the light source on was kept to a
minimum (1–2 min). During recovery after the experiments the
animals were kept warm by cloth instead of using an infrared lamp.
Tissue damage assessment
The damage to the normal mucosa was inspected both visually
and histologically. The appearance of the mucosa was either
photographed or recorded on videotape in the live animal. Images
of the mucosa before treatment were made to serve as a reference.
In the acute experiment, images were made after 24 or 48 h.
Images were taken during each bronchoscopy in the follow-up
experiment. The damage was specified qualitatively as an impres-
sion of the whole treatment field by specifying the amount of
red and white discolouration, oedema and increase of mucus
formation on the mucosa. The damage was scored according to:
none/normal = 0, some/slightly increased = 1, much = 2.
After the experiment, the tracheas were excised and fixed in
buffered formaldehyde (4%). After fixation, the material was cut
and haematoxylin and eosin (H&E) stained for histological
analysis. Longitudinal strips of the whole trachea as well as rings
from the centre of the treated areas were examined. The histo-
logical effects of the treatment were judged partly qualitatively
(for example the nature of the inflammatory cells) and partly quan-
titatively (for example the number of inflammatory cells and the
number of mucus producing cells in the epithelium). The damage
was scored for a panel of histological characteristics according to
no/none = 0, light/few = 1, severe/much = 2. Of these, the most
relevant are discussed in the results.
Table 3 Histological damage scores for acute and follow-up experiment
Sensitizer mTHPC Photofrin
Sacrificed after (days) 1 2 14 1 2 14
Total fluence (J cm–2) 50 25 12.5 50 25 12.5 50 c 274 133 79 190 90 50 65 c
Epithelium
Reduction of 0/1 1/1 1/2 2/0 2/1 2/2 0/1/1/1 0/0/0/0 2 2 2 2 2 2 1 0
mucus-producing cells
Acute inflammation 0/0 0/0 0/1 1/0 1/1 1/1 2/0/1/1 1/0/0/1 1 1 2 0 1 1 0 0
Submucosa
Acute inflammation 1/1 1/2 2/2 1/0 1/1 1/1 1/1/1/1 0/0/0/0 1 1 2 2 2 2 0 0
Oedema 1/1 2/1 2/0 1/1 2/1 1/1 1/1/0/0 0/0/0/1 2 2 1 2 2 1 0 0
Hyperaemia 0/0 0/0 0/0 0/0 0/0 0/0 0/2/0/1 1/0/0/1 2 2 0 2 2 1 1 2
Damage of 1/0 1/0 0/0 0/0 0/0 0/0 0/1/0/0 0/0/0/0 2 2 1 2 2 0 0 0
blood vessels
Atrophy of 1/0 1/1 0/2 1/1 2/1 2/1 0/2/0/1 0/0/0/0 2 2 2 1 1 2 1 1
submucosal glands
Acute inflammation of 0/1 0/1 1/2 1/0 2/1 2/1 0/0/0/0 0/0/0/0 1 0 2 1 1 2 0 0
submucosal glands
Fibrosis 0/0 0/0 0/0 0/0 0/0 0/0 0/1/0/1 0/0/0/0 0 0 0 0 0 0 1 0
No/none = 0, light/few = 1, severe/much = 2. Control values c are taken from sites in a treated trachea which received little or no light (distance from illuminated
area ³ 10 cm).Photofrin versus mTHPC 749
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mTHPC tissue level determination
Tissue samples were taken from the mTHPC-treated animals after
they were sacrificed at 6 and 20 days after injection (2 and 14 days
after treatment). Samples were taken from the skin, trachea (carti-
lage and mucosa in one sample) and oesophagus and were snap-
frozen in liquid nitrogen for further processing. The method of
determining the mTHPC tissue levels with high-performance
liquid chromatography (HPLC) is described by Wang et al (1993).
RESULTS
In Table 1 an overview is given of the treatment parameters. The
treatment sites are coded dist (distal), mid (middle) and prox
(proximal) indicating their position relative to the larynx of the
animal. For each animal the output of the applicator’s diffuser is
specified as well as the measured fluence rate and the total fluence
as measured by the isotropic probe.
General comments
The treatment and follow-up in the acute part of the experiment was
conducted as planned without problems. In the follow-up experi-
ment one animal (no. 3) was excluded from the study because of
technical problems during the illumination that led to uncertainty
about the actual light dose delivered. Furthermore, animal 2 from
the follow-up group had to be sacrificed earlier (day 10) because of
damage to the skin of the belly of the animal. To the best of our
knowledge, this damage was not PDT-related because three other
animals with the same drug dose that were housed and treated under
exactly the same conditions showed no signs of this skin damage.
Moreover, the mTHPC tissue levels of damaged and undamaged
skin samples were not excessively high (10–50 ng g–1, see section
on mTHPC levels). Probably the animal was accidentally exposed
to concentrated, alkaline detergent. Except for this incident, the
general condition of all animals was good during the experiments.
DOSIMETRY
In the case of the acute Photofrin experiment the diffuser output
was fixed and the fluence rate was measured and found to be stable
within 5%, indicating good fixation of the diffuser and the
isotropic probe. The output of the diffuser was checked afterwards
and was found to be stable within 5%.
In the other situations where the output was varied to achieve a
fluence rate of ~ 400 mW cm–2 the output of the diffuser could be
adjusted within seconds after the start of the illumination to reach
the desired level. Once this level was reached, only minor adjust-
ments of the output (≤ 5%) were needed to have a stable (within
5%) reading on the isotropic probe.
The diameters of the tracheas were measured in the microscopic
slides and corrected for the 10% shrinkage due to fixation (Burck,
1973). The diameters were used to calculate the incident fluence
rate and the build-up factor for every field illuminated. The
average trachea diameter in the acute experiment was 1.06 (stan-
dard deviation (s.d.) 0.14) cm, and in the follow-up experiment the
average diameter was 1.12 (s.d. 0.08) cm, which is not signifi-
cantly different despite the 12- or 13-day age difference between
the two groups of animals.
There was no clear difference in b values between 630 (b = 2.1;
s.d. 0.9) and 652 nm (b = 2.6; s.d. 1.2). There was a pronounced
difference, however, in b values between the acute (b = 2.1; s.d.
0.9) and the follow-up group (b = 4.1; s.d. 0.4), which also existed
for the two separate wavelengths. The overall average b value
found was 2.5 (s.d. 1.2) for all animals and wavelengths.
Visual damage score
During each bronchoscopy, an image of the treated areas was
taken and the damage was described qualitatively by specifying
the amount of red and white discolouration, oedema and increase
of mucus formation on the mucosa. The scores indicated in Table 2
give an indication of the entire field treated.
In the acute experiment, the most pronounced damage is found
in the animals treated with Photofrin (3 and 6). All three fields illu-
minated showed redness and oedema in both animals, with slightly
less damage at the proximal site where the lowest fluence was
applied. There was no clear difference between the damage
observed after 24 and after 48 h. The mTHPC-treated animals (1,
2, 4 and 5) showed very little effect in all animals with all applied
fluences. Some whitish discolouration of the tissue was found after
48 h (animals 4 and 5), which was not seen at 24 h. In animal 1
(after 24 h) some mucus was observed.
2.6 mm
DA B C C
D
AB
7
6
5
4
3
2
1
0
02468 1 0
Depth in tissue
N
o
r
m
a
l
i
z
e
d
 
f
l
u
e
n
c
e
 
(
r
a
t
e
)
ms=0 cm–1 ms=100 cm–1
Figure 1 Applicator for light delivery and light dosimetry in the bronchial
tree. (Top) Schematic drawing of the folded applicator in the catheter and
(bottom) of the applicator unfolded in a cylindrical lumen. The cross-section
shows the position of the detector bulb that is pressed against the wall. The
separate components are the light-diffusing fibre at the centre (B), the
isotropic detector (C) and the steel springs of the fixation basket (A). The
outer diameter of the nylon tubing (D) that contains the folded applicator is
2.6 mm. The black dot shown near the proximal end of the applicator
indicates where the detector fibre is attached to the steel spring
Figure 2 Fluence (rate) in tissue for an infinitely wide light beam incident on
a flat, semi-infinite medium of constant optical properties. The fluence (rate)
is normalized to the incident irradiance. Both curves: the absorption
coefficient ma = 0.15 cm–1, the anisotropy factor g = 0.8 and the index of
refraction of the medium n = 1.37. Solid line: ms = 0 cm–1. Dashed line: ms =
100 cm–1. The curves were calculated with Lambert-Beer’s law (ms = 0 cm–1)
and the d-E(4) approximation (ms = 100 cm–1; Star, 1995)750 LHP Murrer et al
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In Figure 3, bronchoscope images are shown of the areas treated
with the highest fluences for both sensitizers, taken 24 h after treat-
ment. In the image taken in the Photofrin-treated animal the red
discolouration (haemorrhage, see Histology), swelling (oedema)
and some excess mucus formation are clearly visible (fluence
274 J cm–2). The image of the mTHPC-treated animal (fluence 50 J
cm–2) shows mucosa with the same appearance as before treatment.
An overview of the tracheas treated with three fluences and
excised and fixed 48 h after treatment is presented in Figure 4. The
Photofrin-treated trachea shows three bands of dark discolouration,
indicating areas where haemorrhage has occurred. The width of the
dark areas is (left to right) 2.5, 2 and 1.5 cm for fluences of 190, 90
and 50 J cm–2 respectively. The trachea of the Photofrin-treated
animal that was sacrificed after 24 h also showed dark discoloured
areas for the middle (133 J cm–2) and high (271 J cm–2) fluences,
although not as sharply demarcated as in the animal sacrificed after
48 h. No clear region of damage was observed for the lowest
fluence (79 J cm–2). The mTHPC-treated tracheas showed no
macroscopical treatment effects, the appearance is quite compa-
rable to that of a normal, untreated trachea (see Figure 4).
A
B
Photofrin
mTHPC
Figure 3 Bronchoscope image of the part of the trachea illuminated with the highest fluence for both sensitizers taken 24 h after treatment. (A) Photofrin
treatment with 274 J cm–2 (630 nm). (B) mTHPC treatment with 50 J cm–2 (652 nm). The black dots in both pictures are bronchoscope imaging artefactsPhotofrin versus mTHPC751
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In the follow-up experiment the overall damage observed visu-
ally was mild (as intended). The mTHPC-treated animals showed
some whitish discolouration and mucus on different days of the
follow-up varying from day 3 to day 10. On day 14 the situation
was normal again. The Photofrin-treated animal showed some
redness on day 3 and some oedema on day 7 (probably non-
specific because of the long time span after illumination). On day
14 the situation had returned to normal, apart from some mucus
formation.
Histology
The major changes in histology are summarized in Table 3, and
some examples of the histology are shown in Figure 4. No
systematic inter-animal variations were observed. A slight chronic
inflammation was present directly beneath the epithelium (lamina
propria) in all animals and was considered as non-specific. For all
experiments the changes were limited to the trachea lining epithe-
lium (lamina propria) and the submucosa. The cartilage or deeper
tissues were not affected in any of the groups, except for fluence
A
B
Photofrin
mTHPC
A Photofrin, 190 J cm-2, Acute
mTHPC, 25 J cm-2, Acute
B
C mTHPC, 50 J cm-2, Follow-up
Figure 4  Overview picture of the dissected and fixed tracheas of animals
sacrificed 48h after treatment. The tracheas were cut lengthwise and
opened. The larynx was located at the right side. (A). Photofrin treatment
with (left to right) 190, 90 and 50J cm–2 (630nm). (B). mTHPC treatment
with (left to right) 50, 25 and 12.4J cm–2 (652nm)
Figure 5Histological slides of the acute and the follow-up experiment (HE
stained). (A) Damage to the trachea 48h after illumination of a Photofrin-
injected animal with a fluence of 190J cm–2. The epithelium is atrophic. The
submucosal glands and blood vessels are damaged and surrounded by
oedema. PMN cells are absent, only sporadic mononuclear cells are seen.
(magnification 253). (B). Damage 48h after illumination (mTHPC, 25J
cm–2). The epithelium shows loss of mucus producing cells. In the
submucosa some oedema and a slight diffuse infiltration of mononuclear
cells is seen. The glands show slight atrophic changes (magnification
1003).(C) Damage 2 weeks after illumination (mTHPC, 50J cm–2). The
trachea appears normal, with epithelium containing mucus-producing cells,
seromucinous glands without atrophy and only slight focal infiltration with
mononuclear cells as is seen in the control tissues. Fibrosis is lacking
(magnification 1003)752 LHP Murrer et al
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independent circumscript mononuclear infiltrates that were found
in the oesophageal glands in two of three mTHPC- and zero of one
Photofrin-treated animals in the acute experiment (of one mTHPC
and one Photofrin animal, no oesophageal tissue was available in
the acute part). In the long-term study oesophageal glands of zero
of four mTHPC and two of two Photofrin animals were found to
contain these infiltrates.
Changes of the respiratory epithelium of the trachea consisted of
increasing seriousness of loss of mucus producing cells, dimin-
ishing number of nuclear rows, flattening of the cells, loss of cilia
and denudation and influx of polymorphonuclear (PMN) cells.
The seromucinous submucosal glands lining the trachea were also
involved in therapy-related damage. They showed an increase of
infiltrating mononuclear cells and, immediately after treatment, of
PMN cells. Loss of mainly mucinous cells, flattening of the epithe-
lial cells and widening of acini is referred to as atrophy of submu-
cosal glands. Mainly, the deep submucosal blood vessels (near the
cartilage) showed hyperaemia. Damage of blood vessels in the
lamina propria and submucosa consisted of frank destruction of
endothelium (nuclear debris and disappearance of endothelium
without inflammatory reaction) and stasis. Only very small areas
with accumulation of coarse collagen bundles were seen occasion-
ally near the submucosa at 2 weeks after illumination.
mTHPC
In the dose-finding experiment no clear correlation between the
applied fluence and severity of changes was observed in the
mTHPC group. A quite intense inflammatory reaction with
oedema and infiltrating PMN cells was seen in the lamina propria
and submucosa for all fluences at day 1 after treatment, while the
epithelium showed a slight or focal decrease of mucus-producing
cells without signs of acute inflammation. In one animal the
submucosal blood vessels showed very slight damage. At 2 days
after treatment, inflammation and oedema were less while mucus
producing cells were almost lacking in the epithelium.
In the follow-up experiment the changes in the treated part of the
trachea compared to the untreated (Table 3) part were only slight
and could be found only in some animals. The changes consisted
only of minor loss of mucus-producing cells in the epithelium and
submucosal glands combined with slight acute inflammation with
some oedema of the submucosa and some hyperaemia. Small areas
of fibrosis were found in the submucosa of two of four animals.
Photofrin
All treated areas in the Photofrin-treated animals showed an imme-
diate severe denudation of the epithelium and loss of mucus-
producing cells that persisted during the second day of treatment.
At both 1 and 2 days after treatment the high fluences caused
severe vascular damage in the lamina propria and submucosa with
stasis, fragmentation of endothelial nuclei, karyolysis and severe
oedema. These severe vascular changes were not observed in
mTHPC-treated animals. One day after treatment a surprisingly
slight infiltration of PMN cells was seen in the Photofrin-treated
animals. Only at day 2 the acute inflammation was severe in all
irradiated fields. Two weeks after the treatment with 65 J cm–2
little difference was seen between the irradiated spot and the
control area. (The control spot of the Photofrin-treated animal that
was excluded from the experiment showed the same characteris-
tics.) A slight loss of submucosal glands and a small area of
fibrosis were found in the submucosa of the treated spot.
Applied fluences for the follow-up experiment
The fluences used in the follow-up experiment were 50 J cm–2 and
65 J cm–2 for mTHPC and Photofrin respectively. The fluences
with potentially recoverable damage were chosen based on the
effects observed in the acute experiment, with the observed visual
and histological damage as a guideline.
For the mTHPC treatment the highest applied fluence of the
acute experiment was used, because both visually and histologi-
cally no severe effects (such as blood vessel damage) were
observed. The Photofrin fluence was chosen as an average of the
lowest dose applied in both animals in the acute experiment. In this
fluence range severe effects started to show as a dark band of
haemorrhage with 79 J cm–2 in the first and no such area in the
second animal with a fluence of 50 J cm–2. Histologically, these
dark bands are the result of hyperaemia, severe damage to blood
vessels and oedema.
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Figure 6 mTHPC levels of pig tissues, taken from animals sacrificed 2 days (acute animals 4 and 5) and 14 days after treatment (follow-up animals 1, 4 and
5). Bars indicate the standard deviationsmTHPC tissue levels
The levels of mTHPC were determined in trachea, oesophagus and
belly skin samples, the data are shown in Figure 4. The trachea
sample (ring height: 5 mm) was taken from a distal part that
received little or no light, and included cartilage as well as mucosa.
The oesophagus sample was taken from the same region (section
of 5 mm). The average value for the mTHPC level in the trachea is
44 ng g–1 (n = 2) at 6 days and remains at a level of
46 ng g–1 (n = 3) at 20 days after injection. The oesophagus level
decreases from 46 ng g–1 (n = 2) at 6 days to 20 ng g–1 (n = 3) at 20
days. The skin drug level at 6 days was highly variable with a
value of 358 and 44 ng g–1 for two different animals. The level at
14 days is more consistent at 18 ng g–1 (n = 3), comparable to the
oesophagus level.
DISCUSSION
Normal tissue damage with Photofrin and mTHPC
During the acute experiment we observed a distinct difference in
normal tissue damage between the Photofrin and mTHPC treat-
ment. The fluences used were based on values used for treatment
of tumours in clinical practice where excessive normal tissue
damage is to be avoided. Therefore such a distinct difference was
not expected. It must be noted that the fluence used in the clinical
QLT/Lederle Photofrin protocol was poorly defined because this
protocol only specifies the output of the linear diffuser irrespective
of the lumen diameter and the optical properties of the mucosa.
The mTHPC total fluences chosen in this study were comparable
to those employed by Savary et al (1994), who used fluences up to
16 J cm–2 of incident light, roughly comparable with the 50 J cm–2
total fluence we used (with the conversion factor 2.5, see
Methods). Photofrin protocols for the treatment of skin lesions use
total irradiances (incident fluences) of 50–100 J cm–2 or higher
(Wilson et al, 1992) with acceptable normal tissue response. With
the conversion factor of 2.5 this indicates a fluence range of
125–250 J cm–2. These fluences are somewhat higher than the total
fluences we measured for the illuminated fields treated according
to the QLT/Lederle protocol, viz. 133 and 90 J cm–2 (mid sections
in the acute animals 3 and 6). In these fields considerable normal
tissue damage was observed at fluences that induce no severe side-
effects in the treatment of skin lesions. Obviously, the light dosi-
metric conversion is just one aspect to take into account when
adapting a protocol written for a specific target for use in an other
organ.
In the mTHPC fluence-finding experiment no clear correlation
between the applied fluence and the normal tissue damage was
observed. The fluence range that was investigated might be below
threshold for the induction of significant effects. Abramson et al
(1994) observed an illumination threshold for the induction of
oedema and erythema in the canine larynx. Unfortunately, the
absolute fluence levels of Abramson’s study and the present work
cannot be compared because the former only specifies the diffuser
output.
The fluences applied in the follow-up experiment did not induce
severe long-term effects (14 days) as could be observed visually as
well as histologically. This result suggests that, while treating a
lesion in the trachea, the normal (sub)mucosa of the trachea of the
pig can withstand a fluence of ~ 50 J cm–2 for both sensitizers for
the drug dose and interval between injection and treatment used
here. The maximum tolerable fluence for mTHPC might be even
higher, as we tested the highest fluence from the acute experiment
in the follow-up experiment. Fifty Joules cm–2 fluence can be
compared (with the reservations noted above) to an incident irradi-
ation of ~ 20 J cm–2, which is already a relatively high ‘light dose’
for skin treatments.
One has to bear in mind, however, that the presence of (pre-)
malignant tissue can alter the pharmacokinetics locally and alter the
sensitivity of the surrounding tissue to PDT. The pharamacokinetics
could be monitored in vivo by a fluorescence measurement to eval-
uate the influence of the presence of malignant tissue (Monnier et al,
1990; Braichotte et al, 1996). A pig tumour model in the trachea
could give more insight in this matter, possibly the technique used
by Hayata et al (1983) to induce an invasive squamous cell carci-
noma in a canine model could be used in the pig also.
Depth of damage
For both sensitizers and all fluences employed, the damage was
limited to the mucosa and the submucosa and did not extend into
or beyond the cartilage. The cartilage structure contains little
blood and has therefore a low oxygen and photosensitizer content
(Lofgren et al, 1994), and is relatively insensitive to photodynamic
therapy. Lofgren observed a concentration of 10 ng g–1 of mTHPC
in the cartilage as opposed to 80 ng g–1 in the mucosa of the canine
larynx, 6 days after injection of 0.3 mg kg–1 mTHPC.
There was no clear light demarcation between damaged and
non-damaged zones in the mucosa for both sensitizers at all
fluences applied. To look into this, the light penetration in the
bronchial mucosa was estimated with the help of a Monte Carlo
model for this geometry (Murrer et al, 1995, 1998). The optical
properties of the mucosa were varied to cover a range of possible
conditions during illumination. The scattering coefficient was
varied from 50 to 100 cm–1 (g = 0.77) and the absorption was
varied from 0.05 to 0.55 cm–1. This range was set around the
optical properties we reported earlier for bronchial mucosa
(Murrer et al, 1995). We found that the penetration in the mucosa
(which is about 1 mm thick) was comparable for all combinations
of optical properties in the set. This was estimated by taking the
average ratio of the fluence rate at 1 mm depth and at the mucosa
surface, which yielded a value of 0.7 (s.d. 0.1). This indicates that
there is no sharp drop in fluence rate to be expected in the 1 mm
mucosa tissue which would cause a demarcation between damaged
and non-damaged tissue. Apparently, the thickness of the cartilage
region (3–4 mm) reduces the fluence rate sufficiently to prevent
induction of observable damage outside the trachea.
Vascular effects
Irreversible vascular damage was observed in the acute Photofrin
experiment. This damage may explain the fact that the influx of PMN
cells (acute inflammation) seems delayed for the highest fluence rates
used. At day 1, only for the lowest fluence applied an extensive
influx of PMN cells is seen, while for the areas treated with higher
fluences severe inflammation only occurs at day 2 (Table 3).
Also with mTHPC vascular effects have been reported (Lofgren
et al, 1994). In our study, vascular effects seem slight and
reversible. Contrary to the Photofrin findings, PMN cell infiltra-
tion was at its maximum on day 1 and reduced on day 2. This
suggests vascular spasm instead of destruction of the vasculature
as seen in the Photofrin animals.
Photofrin versus mTHPC 753
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Fluorescence imaging after injection of mTHPC shows that the
drug content of vascular endothelium reaches a peak at 96 h and
then decreases again (Andrejevic et al, 1996; Savary et al, 1997).
However, Menezes da Silva et al (1995) showed that most exten-
sive vascular occlusion after illumination occurred at 11 h after
mTHPC injection, independently of the blood serum level (peak at
3 h). Their explanation is that vascular damage must result from
damage to other cells than endothelial cells. Our illuminations
were performed much later (96 h) than this time point of maximum
vascular sensitivity to mTHPC–PDT, thus possibly explaining the
lack of irreversible vascular damage in our study.
mTHPC tissue levels
The level of mTHPC in the trachea was determined from samples
containing both the mucosa and the cartilage. From the fact that
the cartilage contains little mTHPC (Lofgren et al, 1994) it can be
concluded that the levels in the mucosa only are higher than those
indicated in Figure 4. The fact that the mTHPC level in the trachea
stays at the same level between 6 and 20 days after injection indi-
cates that the day of treatment can be chosen over a long period of
time (assuming that the ratio of the cartilage/mucosa levels does
not change).
Dosimetry: the build-up factor b
The b-values found in the experiment are lower than the values
found in previous ex vivo experiments (Murrer et al, 1995), and
this can be attributed to the absence of blood in the ex vivo exper-
iment. The blood in the mucosa in the in vivo situation increases
the absorption of the treatment light, thereby lowering the build-up
factor. The b-values found in this experiment agree with those
reported in earlier in vivo experiments on pigs, while b-values in
human volunteers are higher (average 4.7, s.d. 2.2, n = 3) (Murrer
et al, 1997a).
The b-values show large inter-animal variations (average 2.5,
s.d. 1.2), as was also observed in measurements in humans (Murrer
et al, 1997a). This shows the necessity of in situ fluence rate
measurements to assure equal illumination conditions. The pres-
ence of tumour tissue in the trachea may alter the dosimetry.
Lesions often present as a region of whitish discolouration, repre-
senting areas with relatively low absorption of light, causing a
locally higher build-up factor. Haemorrhages (or blood vessels
located near the mucosa surface) induce locally increased absorp-
tion and consequently a lower build-up factor. These influences of
local ‘colour’ are reflected in the intra-animal variations in b
(Table 1).
The difference in b between the acute and the follow-up group
(for both wavelengths) may be caused by variations in the
oxygenation of the blood of the animals. The absorption of the
light by the blood depends on the oxygenation of the blood
(Cheong et al, 1990), which is influenced by the anaesthesia. The
anaesthesia during the two parts of the experiments was conducted
by different operators, which may explain the variations.
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